Joint Clinical Trials Office
CSF Clearance in Sporadic Alzheimer’s Disease
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 25, 2021
The Effects of Iron on Oxidative Stress and Alzheimer’s Disease Biomarkers in Amyloid-Positive and Negative Elderly Individuals
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 25, 2021
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 1, 2021
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 28, 2021
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Sclerosing Cholangitis (VISTAS)
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 7, 2021
Accelerated TMS for Depression and OCD
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 31, 2021
A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects with Type 2 Diabetes on Insulin Therapy
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 2, 2021
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 5, 2021
A Randomized Phase 3 Trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 26, 2021
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination with Ruxolitinib in Participants with Anemia Due to Myeloproliferative Disorders
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 24, 2021